CN117106971A - 用于检测丁型肝炎病毒的核酸组合及试剂盒和应用 - Google Patents
用于检测丁型肝炎病毒的核酸组合及试剂盒和应用 Download PDFInfo
- Publication number
- CN117106971A CN117106971A CN202310590474.5A CN202310590474A CN117106971A CN 117106971 A CN117106971 A CN 117106971A CN 202310590474 A CN202310590474 A CN 202310590474A CN 117106971 A CN117106971 A CN 117106971A
- Authority
- CN
- China
- Prior art keywords
- detection
- hdv
- virus
- nucleic acid
- hepatitis delta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000724709 Hepatitis delta virus Species 0.000 title claims abstract description 127
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 32
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 32
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 31
- 238000001514 detection method Methods 0.000 claims abstract description 113
- 208000037262 Hepatitis delta Diseases 0.000 claims abstract description 86
- 239000000523 sample Substances 0.000 claims abstract description 56
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- 208000029570 hepatitis D virus infection Diseases 0.000 claims abstract description 14
- 238000003745 diagnosis Methods 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 230000003321 amplification Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 12
- 238000012216 screening Methods 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000003908 quality control method Methods 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 7
- 108010006785 Taq Polymerase Proteins 0.000 claims description 6
- 208000005331 Hepatitis D Diseases 0.000 claims description 5
- 102100034343 Integrase Human genes 0.000 claims description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000003161 ribonuclease inhibitor Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 claims description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 229960003237 betaine Drugs 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 claims description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 claims description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 claims description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 229940074410 trehalose Drugs 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 238000002651 drug therapy Methods 0.000 claims description 2
- 101710163270 Nuclease Proteins 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 19
- 241000700605 Viruses Species 0.000 abstract description 13
- 230000035945 sensitivity Effects 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 210000002966 serum Anatomy 0.000 abstract description 6
- 230000005540 biological transmission Effects 0.000 abstract description 5
- 102000053642 Catalytic RNA Human genes 0.000 abstract description 3
- 108090000994 Catalytic RNA Proteins 0.000 abstract description 3
- 238000003748 differential diagnosis Methods 0.000 abstract description 3
- 108091092562 ribozyme Proteins 0.000 abstract description 3
- 239000000969 carrier Substances 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- -1 HDV nucleic acid Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 description 20
- 239000000975 dye Substances 0.000 description 16
- 210000002381 plasma Anatomy 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 241000700721 Hepatitis B virus Species 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 230000037029 cross reaction Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000010206 sensitivity analysis Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- JZODKRWQWUWGCD-UHFFFAOYSA-N 2,5-di-tert-butylbenzene-1,4-diol Chemical compound CC(C)(C)C1=CC(O)=C(C(C)(C)C)C=C1O JZODKRWQWUWGCD-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 101710158865 Large delta antigen Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000012952 Resampling Methods 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108091006611 SLC10A1 Proteins 0.000 description 1
- 241001515849 Satellite Viruses Species 0.000 description 1
- 102100021988 Sodium/bile acid cotransporter Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
- 229950001750 lonafarnib Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 230000009265 virologic response Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
序号 | 物料名称 | 加入量/μL | 终浓度 |
1 | 10*Anstart Buffer | 2.5 | 1* |
2 | 10mM dNTPs | 0.5 | 0.2mM |
3 | 10μM上游引物 | 0.5 | 0.2μM |
4 | 10μM下游引物 | 0.5 | 0.2μM |
5 | 10μM探针 | 0.25 | 0.1μM |
6 | Taq DNA聚合酶 | 0.5 | 0.1U/μL |
7 | NF-Water | 补足体积至25 | / |
序号 | 名称 | 终浓度 |
1 | Heat-UNG酶 | 0.01U/μL |
2 | RNasin | 1U/μL |
3 | M-MLV逆转录酶 | 0.1U/μL |
4 | Taq DNA聚合酶 | 0.1U/μL |
序号 | 名称 | 单个反应加入量/μL |
1 | HDV PCR反应液 | 18 |
2 | HDV PCR酶液 | 2 |
3 | RNA样本 | 20 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310590474.5A CN117106971A (zh) | 2023-05-24 | 2023-05-24 | 用于检测丁型肝炎病毒的核酸组合及试剂盒和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310590474.5A CN117106971A (zh) | 2023-05-24 | 2023-05-24 | 用于检测丁型肝炎病毒的核酸组合及试剂盒和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117106971A true CN117106971A (zh) | 2023-11-24 |
Family
ID=88802707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310590474.5A Pending CN117106971A (zh) | 2023-05-24 | 2023-05-24 | 用于检测丁型肝炎病毒的核酸组合及试剂盒和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117106971A (zh) |
-
2023
- 2023-05-24 CN CN202310590474.5A patent/CN117106971A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111235316B (zh) | 鉴定新型冠状病毒的引物探针及在三重荧光rpa的应用 | |
CN100441698C (zh) | 基于环介导的等温扩增技术的血液病毒核酸筛查方法 | |
Monpoeho et al. | Application of a real-time polymerase chain reaction with internal positive control for detection and quantification of enterovirus in cerebrospinal fluid | |
CN113881812B (zh) | 检测SARS-CoV-2突变株的组合物、试剂盒、方法及其用途 | |
CN109182600B (zh) | 一种同步检测乙型肝炎病毒、丙型肝炎病毒、人免疫缺陷病毒1型的荧光定量pcr试剂盒 | |
CN111286557B (zh) | 一种检测输血性传播病原体的试剂组合、试剂盒及应用 | |
WO2010102460A1 (zh) | 定性定量检测病原微生物遗传物质的方法及其试剂盒 | |
CN109517927A (zh) | 一种甲型、乙型流感病毒快速分型检测试剂盒及其应用 | |
CN108977580A (zh) | 一种2-8℃保存的快速检测丙型肝炎病毒核酸的试剂盒 | |
CN110923361B (zh) | 基于数字pcr用于血源筛查的引物、探针及试剂盒 | |
CN102559930A (zh) | 一种荧光定量rt-pcr检测丙型肝炎病毒的试剂盒 | |
CN105483283A (zh) | 丙型肝炎病毒hcv实时荧光核酸恒温扩增检测试剂盒 | |
Xiao et al. | Comparative evaluation of a triplex nucleic acid test for detection of HBV DNA, HCV RNA, and HIV-1 RNA, with the Procleix Tigris System | |
CN113046484B (zh) | 用于检测非洲猪瘟病毒p72基因的引物探针、试剂盒及方法 | |
Frankel et al. | Development of a high-throughput multiplexed real time RT-PCR assay for detection of human pegivirus 1 and 2 | |
US20230250497A1 (en) | One-step nested pcr primers set and kit modified with locked nucleic acid for detecting african swine fever virus | |
CN105463131A (zh) | 人博卡病毒lamp检测试剂盒 | |
CN117106971A (zh) | 用于检测丁型肝炎病毒的核酸组合及试剂盒和应用 | |
Ibrahim et al. | Molecular Detection of Occult Hepatitis B virus in plasma and urine of renal transplant patients in Khartoum state Sudan | |
CN105567867B (zh) | 人类免疫缺陷病毒1型实时荧光核酸恒温扩增检测试剂盒 | |
CN102952897A (zh) | 一种风疹病毒rt-pcr荧光检测试剂盒及检测方法 | |
CN107385116B (zh) | 一种检测1型人类免疫缺陷病毒的方法及其专用成套试剂 | |
CN109852732A (zh) | 荧光定量pcr隐匿性乙肝病毒检测试剂盒 | |
CN113025756B (zh) | 一种用于检测hcv 1型耐药突变基因的检测方法及应用 | |
Forčić et al. | Incidence of hepatitis C virus RNA in anti-HCV negative plasma pools in Croatia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240411 Address after: 518116 Yahui Long Biotechnology Plant, Baolong Street, Longgang District, Shenzhen City, Guangdong Province Applicant after: SHENZHEN YHLO BIOTECH Co.,Ltd. Country or region after: China Applicant after: Peking University Address before: 518116 Yahui Long Biotechnology Plant, Baolong Street, Longgang District, Shenzhen City, Guangdong Province Applicant before: SHENZHEN YHLO BIOTECH Co.,Ltd. Country or region before: China |
|
TA01 | Transfer of patent application right |